Curis, Inc. (NASDAQ:CRIS) Short Interest Down 39.4% in December

Curis, Inc. (NASDAQ:CRIS) saw a large decline in short interest in December. As of December 15th, there was short interest totalling 44,900 shares, a decline of 39.4% from the November 30th total of 74,100 shares. Based on an average trading volume of 59,400 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.6% of the company’s stock are short sold.

Curis Trading Down 0.9 %

Curis stock opened at $3.14 on Friday. The company has a market capitalization of $26.59 million, a P/E ratio of -0.40 and a beta of 3.34. The firm’s fifty day simple moving average is $4.15 and its 200-day simple moving average is $5.32. Curis has a 1-year low of $3.05 and a 1-year high of $17.49.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Curis stock. Point72 Asset Management L.P. boosted its position in shares of Curis, Inc. (NASDAQ:CRIS) by 795.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 108,356 shares of the biotechnology company’s stock after acquiring an additional 96,256 shares during the period. Point72 Asset Management L.P. owned approximately 1.84% of Curis worth $748,000 at the end of the most recent quarter. 29.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Curis in a research note on Tuesday, December 10th.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.